Entering text into the input field will update the search result below

Acceleron Pharma: Potential Catalysts Ahead

Mar. 02, 2020 1:10 PM ETMerck & Co., Inc. (MRK)BMY1 Comment
Healthcare on the Move profile picture
Healthcare on the Move


  • Reblozyl franchise will be key revenue driver for the company in 2020.
  • The company has a robust mid and late-stage research pipeline.
  • Investors should be aware of risks such as R&D failure risks, regulatory risks, and market uncertainty risks.

Today, we will study why Acceleron Pharma (XLRN) can be an attractive pick in 2020.

Company overview

Acceleron Pharma is a biotechnology company focused on developing and commercializing medicines which selectively target multiple ligands (proteins) in the TGF-beta superfamily. These proteins play a major role in the pathogenesis of several major diseases. The company's lead asset, Reblozyl (luspatercept-aamt) has been already approved by the FDA for treatment of anemia in adult patients with beta-thalassemia who require regular red blood cell transfusions. Developed in partnership with Celgene (CELG), now a part of Bristol-Myers Squibb (BMY), Reblozyl is a first-in-class erythroid (red blood cell) maturation agent being developed to treat patients who have serious blood disorders associated with ineffective erythropoiesis.

Besides this indication, the company is also studying Reblozyl in non-transfusion dependent beta-thalassemia indication, MDS (Myelodysplastic Syndromes), and Myelofibrosis. Acceleron is also studying Sotatercept in PAH (pulmonary arterial hypertension) and ACE-1334 in pulmonary disease indications. Finally, the company is studying ACE-083 in Charcot-Marie-Tooth Disease indication.

Founded in 2003, Acceleron has headquarters at Cambridge, Massachusetts. The company went public in 2013.

Reblozyl is a key revenue driver for Acceleron in 2020

In November 2019, FDA approved Acceleron Pharma and Bristol-Myers Squibb's Reblozyl (luspatercept-aamt) for the treatment of anemia in adult patients with beta-thalassemia who require regular RBC (red blood cell) transfusions. The approval was based on results of the Phase 3 trial, BELIEVE. Long-term results from this trial have demonstrated strong clinical benefit of at least a 33% reduction in RBC transfusion burden over any 24-week period in more than 45% of patients and median duration of almost 18 months in the Reblozyl arm. The most common adverse events of bone pain, arthralgia and dizziness also decreased in intensity over time. The approved indication targets a small population of about 1,000 or 1,500 patients in the U.S. The company launched the drug at the end of

This article was written by

Healthcare on the Move profile picture
I am an MBA in finance and an engineering graduate. I have also completed the CFA certification.I am involved in international trade and have been passionately tracking global equity markets for more than 7 years. I mainly focus on spotting long-term value investments in biotechnology, pharmaceutical, hospital, and medical device sectors. In the last two years, I have also been studying cannabis and hemp sectors.

Analyst’s Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.